Vector Prime-protein Boost Vaccine for Breast Cancer

• 作 者: AlbertDeisseroth;YuchengTang;HakanAkbulut;LinePetersen;NagyHabib;
• 机 构: Food and Drug Administration USA
• 出 处: (BITs 3rd Annual World Cancer Congress-2010, Breast Cancer C
• 发表日期: 2010年期

　　Unfortunately, it has been known for a long time that the immune response is diminished in older individuals due to acquisition of quantitative and functional defects in CD4 cells (eg.diminished expression of the CD40L in activated CD4 T cells).The presence of the CD40L on the CD4 helper T cells is important for vaccine induced expansion of antigen specific T cells and B cells.In order to overcome these problems, we developed an Ad-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost vaccine.The Ad-sig-TAA/ecdCD40L carries a transcription unit encoding the extracellular domain (ecd) of the CD40 ligand (CD40L) linked to tumor associated antigen (TAA).The CD40L targets the TAA to the dendritic cells (DCs), activates the DCs, and carries the TAA into the DC so that the TAA fragments are presented on Class Ⅰ MHC.